… treatment to more than one pathway should provide therapeutic advantages [… preliminary
experience of targeted therapy with bevacizumab and erlotinib tailored to the molecular profile …

… molecular screening for personalization of targeted therapy in … a patient suffering from
recurrent GBM who was treated with bevacizumab and erlotinib tailored to the molecular profile of …

… came into common use for recurrent GBM at many academic … Continued effort to tailor treatment
by molecular profile will … Preliminary results for this study were presented in abstract form …

… of GBM treatment on the horizon are targeted therapy utilizing … In preliminary studies, we
prospectively selected recurrent … ), 14 bevacizumab plus erlotinib (bev+erl) and 4 bevacizumab …

… gliomas and to evaluat the efficacy of vorinostat + erlotinib … bevacizumab alone or in
combination with irinotecan was well tolerated and effective in patients with recurrent glioblastoma […

… EGFR tyrosine kinase inhibitors (TKI) erlotinib and gefitinb [45, 46]. … plus bevacizumab
in EGFRvIII-positive recurrent glioblastoma. … Preliminary data from a phase I trial of ABT-414 …

… approved bevacizumab as a single agent for recurrent GBM … study, patients with progressive
or recurrent GBM received erlotinib (… ) showed the promising preliminary antitumor activity of …

… (rapamycin) combined with gefitinib, erlotinib, or AEE788. A … in unselected recurrent
glioblastoma patients were recently … bevacizumab combined with irinotecan in malignant gliomas …

… II study of erlotinib in patients with recurrent EGFR‑ positive … Three Phase II trials are currently
ongoing using bevacizumab … ongoing trials targeting PDGFR for recurrent GBM patients. …

… of imatinib in recurrent gliomas, and preliminary results showed … of sorafenib and erlotinib
for patients with recurrent GBM, … comparing the effect of bevacizumab alone or in combination …